| Autor: |
Hou, Mimi M., Barrett, Jordan R., Themistocleous, Yrene, Rawlinson, Thomas A., Diouf, Ababacar, Martinez, Francisco J., Nielsen, Carolyn M., Lias, Amelia M., King, Lloyd D. W., Edwards, Nick J., Greenwood, Nicola M., Kingham, Lucy, Poulton, Ian D., Khozoee, Baktash, Goh, Cyndi, Hodgson, Susanne H., Mac Lochlainn, Dylan J., Salkeld, Jo, Guillotte-Blisnick, Micheline, Huon, Christèle |
| Předmět: |
|
| Zdroj: |
Science Translational Medicine; 7/12/2023, Vol. 15 Issue 704, p1-12, 12p |
| Abstrakt: |
There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II (PvDBPII). Recombinant viral vaccines using chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) vectors as well as a protein and adjuvant formulation (PvDBPII/Matrix-M) were tested in both a standard and a delayed dosing regimen. Volunteers underwent controlled human malaria infection (CHMI) after their last vaccination, alongside unvaccinated controls. Efficacy was assessed by comparisons of parasite multiplication rates in the blood. PvDBPII/Matrix-M, given in a delayed dosing regimen, elicited the highest antibody responses and reduced the mean parasite multiplication rate after CHMI by 51% (n = 6) compared with unvaccinated controls (n = 13), whereas no other vaccine or regimen affected parasite growth. Both viral-vectored and protein vaccines were well tolerated and elicited expected, short-lived adverse events. Together, these results support further clinical evaluation of the PvDBPII/Matrix-M P. vivax vaccine. Editor's summary: Plasmodium vivax is the second most common cause of malaria in humans and currently lacks an effective vaccine. Here, Hou et al. report encouraging clinical trial results testing the safety and efficacy of two vaccine candidates, both based on the P. vivax Duffy-binding protein region II (PvDBPII). One of the vaccine candidates, an adjuvanted PvDBPII protein vaccine, elicited the strongest antibody responses, particularly when delivered in a delayed dosing regimen. This correlated with the superior control of parasitemia when vaccinees underwent a controlled human malaria infection. These data, plus a favorable safety profile, support further clinical testing of this vaccine regimen. —Courtney Malo [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
